Fig. 4: MALDI imaging of cultured cardiomyocytes reveals profound differences in the metabolic signature of FGF23 and vehicle-treated cells. | npj Metabolic Health and Disease

Fig. 4: MALDI imaging of cultured cardiomyocytes reveals profound differences in the metabolic signature of FGF23 and vehicle-treated cells.

From: Deletion of cardiac fibroblast growth factor-23 beneficially impacts myocardial energy metabolism in left ventricular hypertrophy

Fig. 4

A Heatmap of the top 1000 significantly different metabolites and B PLS-DA score plot of the metabolome reveals distinct differences in the metabolic signatures of recombinant FGF23 (rFGF23) and vehicle-treated neonatal rat cardiomyocytes. C Intensity distribution maps and box plots of Hex1P1 and HexNac1S1 demonstrate an increase in abundance in rFGF23-treated vs. vehicle-treated cardiomyocytes. D Energy charge shows no differences between vehicle and rFGF23-treated cells. AMP, ADP, and ATP intensity distributions in vehicle- and rFGF23-treated cells are shown as an example. E Abundance of DHAP(O-18:0) remains unchanged under rFGF23 treatment in cultured cardiomyocytes as shown by intensity distribution maps and box plots. Data in (A–D) are from 3 independent cultures each. *p < 0.05, **p < 0.01 by two-tailed t-test. ns not significant, Hex hexose, HexNAc N-acetylhexosamine, P phosphate, S sulfate.

Back to article page